Structure‐activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion

1 The effects of pyrimidines and purines on the d.c. potential of the rat isolated superior cervical ganglion (SCG) have been examined by a grease‐gap technique to determine the structure‐activity requirements of the receptor activated by pyrimidines, i.e. a pyrimidinoceptor. 2 5‐Ammoimidazole‐4‐car...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 1995-11, Vol.116 (6), p.2764-2770
Hauptverfasser: Connolly, G.P., Harrison, P. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2770
container_issue 6
container_start_page 2764
container_title British journal of pharmacology
container_volume 116
creator Connolly, G.P.
Harrison, P. J.
description 1 The effects of pyrimidines and purines on the d.c. potential of the rat isolated superior cervical ganglion (SCG) have been examined by a grease‐gap technique to determine the structure‐activity requirements of the receptor activated by pyrimidines, i.e. a pyrimidinoceptor. 2 5‐Ammoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranosyl (ZTP), the pyrimidines, cytidine 5′‐triphosphate (CTP), uridine 5′‐triphosphate (UTP) and thymidine 5′‐triphosphate (TIT) and the purines, adenosine 5′‐triphosphate (ATP; in the presence of an A1‐purinoceptor antagonist 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) (1 μ)), adenosine 5′‐O‐(3‐thiotriphosphate) (ATPγS), guanosine 5′‐triphosphate (GTP), inosine 5′‐triphosphate (ITP) depolarized ganglia in a concentration‐dependent manner. The relative order of ZTP and purine 5′‐triphosphates in depolarizing ganglia was ZTP≥ATPγS > > ATP ≥ ITP=GTP, and for the pyrimidine 5′‐triphosphates UTP > TTP ≥ CTP. Depolarizations evoked by ATPγS were followed by concentration‐dependent hyperpolarizations at 100 and 1000 μm. 3 At concentrations of between 0.1 μm and 1 mm, uridine 5′‐diphosphate (UDP), uridine 5′‐diphospho‐glucose (UDPG) and uridine 5′‐diphosphoglucuronic acid (UDPGA) evoked significant and concentration‐dependent depolarizations, whereas uridine 5′‐monophosphate (UMP), uridine and uracil were inactive or produced small (< 45 μV) depolarizations. The relative order of potency of uridine analogues in depolarizing ganglia was UDP ≥ UTP > UDPG > UDPGA > > uracil≥ UMP=pseudour‐idine≥ uridine. At 3 and 10 mm, uridine produced concentration‐dependent hyperpolarizations. Nikkomycin Z, a nucleoside resembling UTP (viz. the triphosphate chain at the 5′‐position on the ribose moiety being replaced by a peptide), was inactive between 1 μm and 1 mm. Generally, a concentration of 10 mm was required before thymidine, 6‐azathymine, 6‐azauracil or 6‐azauridine depolarized ganglia. 4 Suramin (300 μm), a P2‐purinoceptor antagonist, significantly depressed depolarizations evoked by α,β‐methylene‐ATP (α,β‐MeATP; 100 μm), ATPγS (100 μm), CTP (1 μm), GTP (1 μm), ZTP (30 μm) and ATP (300 μm) in the presence of DPCPX (1 μm). Suramin reversed a small depolarization evoked by UMP (1 μm) into a small hyperpolarization. In contrast depolarizations evoked by UDP, UTP, UDPG (all at 100 μm) and TTP (300 μm) were unaltered or enhanced by suramin. 5 It is concluded that the rat SCG contains distinct nucleotide receptors including a P2‐purinoceptor (activated by α,β‐MeA
doi_str_mv 10.1111/j.1476-5381.1995.tb17239.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1909137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77827649</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5389-135bcdb682a510c5955db1c587c55f1681614907e369b8dac258eb7485d5f50a3</originalsourceid><addsrcrecordid>eNqVkdGK1DAUhoMo67j6CEIQ8a41p53TJF6IuqgrLCio1yFN05kMnbYm6bhzt4-wz-iTmNkpg16JuWnC95-fv-cn5BmwHNJ5uclhyasMSwE5SIl5rIEXpcyv75HFCd0nC8YYzwCEeEgehbBhLEGOZ-RMoATGigVxX6OfTJy8_XVzq010Oxf31NtORzf0Ye1GOrRU03Hv3dY1rrcJGjvGwVPX07hObx2pC0OasA0N02i9S9BYv3NGd3Sl-1WXvB6TB63ugn0yf8_J9w_vv11cZlefP366eHuVmRRaZlBibZq6EoVGYAYlYlODQcENYguVgAqWknFbVrIWjTYFClvzpcAGW2S6PCevj77jVG9tY2wfve7UmPJrv1eDdupv0ru1Wg07BZJJKHkyeDEb-OHHZENUWxeM7Trd22EKinNR8Gop_ykEztK6JSbhq6PQ-CEEb9tTGmDq0KjaqENt6lCbOjSq5kbVdRp--uf_nEbnChN_PnMd0r5br3vjwklWpF3hXdg3R9lP19n9fwRQ775c3l3L32PmwgM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17047795</pqid></control><display><type>article</type><title>Structure‐activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Connolly, G.P. ; Harrison, P. J.</creator><creatorcontrib>Connolly, G.P. ; Harrison, P. J.</creatorcontrib><description>1 The effects of pyrimidines and purines on the d.c. potential of the rat isolated superior cervical ganglion (SCG) have been examined by a grease‐gap technique to determine the structure‐activity requirements of the receptor activated by pyrimidines, i.e. a pyrimidinoceptor. 2 5‐Ammoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranosyl (ZTP), the pyrimidines, cytidine 5′‐triphosphate (CTP), uridine 5′‐triphosphate (UTP) and thymidine 5′‐triphosphate (TIT) and the purines, adenosine 5′‐triphosphate (ATP; in the presence of an A1‐purinoceptor antagonist 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) (1 μ)), adenosine 5′‐O‐(3‐thiotriphosphate) (ATPγS), guanosine 5′‐triphosphate (GTP), inosine 5′‐triphosphate (ITP) depolarized ganglia in a concentration‐dependent manner. The relative order of ZTP and purine 5′‐triphosphates in depolarizing ganglia was ZTP≥ATPγS &gt; &gt; ATP ≥ ITP=GTP, and for the pyrimidine 5′‐triphosphates UTP &gt; TTP ≥ CTP. Depolarizations evoked by ATPγS were followed by concentration‐dependent hyperpolarizations at 100 and 1000 μm. 3 At concentrations of between 0.1 μm and 1 mm, uridine 5′‐diphosphate (UDP), uridine 5′‐diphospho‐glucose (UDPG) and uridine 5′‐diphosphoglucuronic acid (UDPGA) evoked significant and concentration‐dependent depolarizations, whereas uridine 5′‐monophosphate (UMP), uridine and uracil were inactive or produced small (&lt; 45 μV) depolarizations. The relative order of potency of uridine analogues in depolarizing ganglia was UDP ≥ UTP &gt; UDPG &gt; UDPGA &gt; &gt; uracil≥ UMP=pseudour‐idine≥ uridine. At 3 and 10 mm, uridine produced concentration‐dependent hyperpolarizations. Nikkomycin Z, a nucleoside resembling UTP (viz. the triphosphate chain at the 5′‐position on the ribose moiety being replaced by a peptide), was inactive between 1 μm and 1 mm. Generally, a concentration of 10 mm was required before thymidine, 6‐azathymine, 6‐azauracil or 6‐azauridine depolarized ganglia. 4 Suramin (300 μm), a P2‐purinoceptor antagonist, significantly depressed depolarizations evoked by α,β‐methylene‐ATP (α,β‐MeATP; 100 μm), ATPγS (100 μm), CTP (1 μm), GTP (1 μm), ZTP (30 μm) and ATP (300 μm) in the presence of DPCPX (1 μm). Suramin reversed a small depolarization evoked by UMP (1 μm) into a small hyperpolarization. In contrast depolarizations evoked by UDP, UTP, UDPG (all at 100 μm) and TTP (300 μm) were unaltered or enhanced by suramin. 5 It is concluded that the rat SCG contains distinct nucleotide receptors including a P2‐purinoceptor (activated by α,β‐MeATP, ATP, GTP, ITP and ZTP) and a pyrimidinoceptor (activated by UTP, UDP, UDPG, UDPGA and TTP). The pyrimidinoceptor on rat SCG neurones had specific structure activity requirements with the di‐ and triphosphates of uridine being the most effective depolarizing agonists examined.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/j.1476-5381.1995.tb17239.x</identifier><identifier>PMID: 8591002</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adenosine 5′‐triphosphate ; Aminoglycosides ; Aminoimidazole Carboxamide - pharmacology ; Animals ; Anti-Bacterial Agents - pharmacology ; Biological and medical sciences ; Fundamental and applied biological sciences. Psychology ; Male ; Membrane Potentials - drug effects ; nucleotide ; P2‐purinoceptor ; Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ ; Pyrimidine Nucleosides - metabolism ; Pyrimidine Nucleosides - pharmacology ; Pyrimidine Nucleotides - metabolism ; Pyrimidine Nucleotides - pharmacology ; Pyrimidines - metabolism ; Pyrimidines - pharmacology ; pyrimidinoceptor ; Rats ; Rats, Sprague-Dawley ; Receptors, Cell Surface - drug effects ; Receptors, Cell Surface - physiology ; Ribonucleotides - pharmacology ; Structure-Activity Relationship ; superior cervical ganglion (SCG) ; Superior Cervical Ganglion - drug effects ; Superior Cervical Ganglion - ultrastructure ; Suramin - pharmacology ; Uridine - analogs &amp; derivatives ; Uridine - pharmacology ; uridine 5′‐triphosphate ; Uridine Triphosphate - pharmacology ; Vertebrates: nervous system and sense organs</subject><ispartof>British journal of pharmacology, 1995-11, Vol.116 (6), p.2764-2770</ispartof><rights>1995 British Pharmacological Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5389-135bcdb682a510c5955db1c587c55f1681614907e369b8dac258eb7485d5f50a3</citedby><cites>FETCH-LOGICAL-c5389-135bcdb682a510c5955db1c587c55f1681614907e369b8dac258eb7485d5f50a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1909137/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1909137/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2907549$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8591002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Connolly, G.P.</creatorcontrib><creatorcontrib>Harrison, P. J.</creatorcontrib><title>Structure‐activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>1 The effects of pyrimidines and purines on the d.c. potential of the rat isolated superior cervical ganglion (SCG) have been examined by a grease‐gap technique to determine the structure‐activity requirements of the receptor activated by pyrimidines, i.e. a pyrimidinoceptor. 2 5‐Ammoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranosyl (ZTP), the pyrimidines, cytidine 5′‐triphosphate (CTP), uridine 5′‐triphosphate (UTP) and thymidine 5′‐triphosphate (TIT) and the purines, adenosine 5′‐triphosphate (ATP; in the presence of an A1‐purinoceptor antagonist 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) (1 μ)), adenosine 5′‐O‐(3‐thiotriphosphate) (ATPγS), guanosine 5′‐triphosphate (GTP), inosine 5′‐triphosphate (ITP) depolarized ganglia in a concentration‐dependent manner. The relative order of ZTP and purine 5′‐triphosphates in depolarizing ganglia was ZTP≥ATPγS &gt; &gt; ATP ≥ ITP=GTP, and for the pyrimidine 5′‐triphosphates UTP &gt; TTP ≥ CTP. Depolarizations evoked by ATPγS were followed by concentration‐dependent hyperpolarizations at 100 and 1000 μm. 3 At concentrations of between 0.1 μm and 1 mm, uridine 5′‐diphosphate (UDP), uridine 5′‐diphospho‐glucose (UDPG) and uridine 5′‐diphosphoglucuronic acid (UDPGA) evoked significant and concentration‐dependent depolarizations, whereas uridine 5′‐monophosphate (UMP), uridine and uracil were inactive or produced small (&lt; 45 μV) depolarizations. The relative order of potency of uridine analogues in depolarizing ganglia was UDP ≥ UTP &gt; UDPG &gt; UDPGA &gt; &gt; uracil≥ UMP=pseudour‐idine≥ uridine. At 3 and 10 mm, uridine produced concentration‐dependent hyperpolarizations. Nikkomycin Z, a nucleoside resembling UTP (viz. the triphosphate chain at the 5′‐position on the ribose moiety being replaced by a peptide), was inactive between 1 μm and 1 mm. Generally, a concentration of 10 mm was required before thymidine, 6‐azathymine, 6‐azauracil or 6‐azauridine depolarized ganglia. 4 Suramin (300 μm), a P2‐purinoceptor antagonist, significantly depressed depolarizations evoked by α,β‐methylene‐ATP (α,β‐MeATP; 100 μm), ATPγS (100 μm), CTP (1 μm), GTP (1 μm), ZTP (30 μm) and ATP (300 μm) in the presence of DPCPX (1 μm). Suramin reversed a small depolarization evoked by UMP (1 μm) into a small hyperpolarization. In contrast depolarizations evoked by UDP, UTP, UDPG (all at 100 μm) and TTP (300 μm) were unaltered or enhanced by suramin. 5 It is concluded that the rat SCG contains distinct nucleotide receptors including a P2‐purinoceptor (activated by α,β‐MeATP, ATP, GTP, ITP and ZTP) and a pyrimidinoceptor (activated by UTP, UDP, UDPG, UDPGA and TTP). The pyrimidinoceptor on rat SCG neurones had specific structure activity requirements with the di‐ and triphosphates of uridine being the most effective depolarizing agonists examined.</description><subject>Adenosine 5′‐triphosphate</subject><subject>Aminoglycosides</subject><subject>Aminoimidazole Carboxamide - pharmacology</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Male</subject><subject>Membrane Potentials - drug effects</subject><subject>nucleotide</subject><subject>P2‐purinoceptor</subject><subject>Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ</subject><subject>Pyrimidine Nucleosides - metabolism</subject><subject>Pyrimidine Nucleosides - pharmacology</subject><subject>Pyrimidine Nucleotides - metabolism</subject><subject>Pyrimidine Nucleotides - pharmacology</subject><subject>Pyrimidines - metabolism</subject><subject>Pyrimidines - pharmacology</subject><subject>pyrimidinoceptor</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Cell Surface - drug effects</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Ribonucleotides - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>superior cervical ganglion (SCG)</subject><subject>Superior Cervical Ganglion - drug effects</subject><subject>Superior Cervical Ganglion - ultrastructure</subject><subject>Suramin - pharmacology</subject><subject>Uridine - analogs &amp; derivatives</subject><subject>Uridine - pharmacology</subject><subject>uridine 5′‐triphosphate</subject><subject>Uridine Triphosphate - pharmacology</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkdGK1DAUhoMo67j6CEIQ8a41p53TJF6IuqgrLCio1yFN05kMnbYm6bhzt4-wz-iTmNkpg16JuWnC95-fv-cn5BmwHNJ5uclhyasMSwE5SIl5rIEXpcyv75HFCd0nC8YYzwCEeEgehbBhLEGOZ-RMoATGigVxX6OfTJy8_XVzq010Oxf31NtORzf0Ye1GOrRU03Hv3dY1rrcJGjvGwVPX07hObx2pC0OasA0N02i9S9BYv3NGd3Sl-1WXvB6TB63ugn0yf8_J9w_vv11cZlefP366eHuVmRRaZlBibZq6EoVGYAYlYlODQcENYguVgAqWknFbVrIWjTYFClvzpcAGW2S6PCevj77jVG9tY2wfve7UmPJrv1eDdupv0ru1Wg07BZJJKHkyeDEb-OHHZENUWxeM7Trd22EKinNR8Gop_ykEztK6JSbhq6PQ-CEEb9tTGmDq0KjaqENt6lCbOjSq5kbVdRp--uf_nEbnChN_PnMd0r5br3vjwklWpF3hXdg3R9lP19n9fwRQ775c3l3L32PmwgM</recordid><startdate>199511</startdate><enddate>199511</enddate><creator>Connolly, G.P.</creator><creator>Harrison, P. J.</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199511</creationdate><title>Structure‐activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion</title><author>Connolly, G.P. ; Harrison, P. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5389-135bcdb682a510c5955db1c587c55f1681614907e369b8dac258eb7485d5f50a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adenosine 5′‐triphosphate</topic><topic>Aminoglycosides</topic><topic>Aminoimidazole Carboxamide - pharmacology</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Male</topic><topic>Membrane Potentials - drug effects</topic><topic>nucleotide</topic><topic>P2‐purinoceptor</topic><topic>Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ</topic><topic>Pyrimidine Nucleosides - metabolism</topic><topic>Pyrimidine Nucleosides - pharmacology</topic><topic>Pyrimidine Nucleotides - metabolism</topic><topic>Pyrimidine Nucleotides - pharmacology</topic><topic>Pyrimidines - metabolism</topic><topic>Pyrimidines - pharmacology</topic><topic>pyrimidinoceptor</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Cell Surface - drug effects</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Ribonucleotides - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>superior cervical ganglion (SCG)</topic><topic>Superior Cervical Ganglion - drug effects</topic><topic>Superior Cervical Ganglion - ultrastructure</topic><topic>Suramin - pharmacology</topic><topic>Uridine - analogs &amp; derivatives</topic><topic>Uridine - pharmacology</topic><topic>uridine 5′‐triphosphate</topic><topic>Uridine Triphosphate - pharmacology</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Connolly, G.P.</creatorcontrib><creatorcontrib>Harrison, P. J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Connolly, G.P.</au><au>Harrison, P. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structure‐activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>1995-11</date><risdate>1995</risdate><volume>116</volume><issue>6</issue><spage>2764</spage><epage>2770</epage><pages>2764-2770</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>1 The effects of pyrimidines and purines on the d.c. potential of the rat isolated superior cervical ganglion (SCG) have been examined by a grease‐gap technique to determine the structure‐activity requirements of the receptor activated by pyrimidines, i.e. a pyrimidinoceptor. 2 5‐Ammoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranosyl (ZTP), the pyrimidines, cytidine 5′‐triphosphate (CTP), uridine 5′‐triphosphate (UTP) and thymidine 5′‐triphosphate (TIT) and the purines, adenosine 5′‐triphosphate (ATP; in the presence of an A1‐purinoceptor antagonist 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) (1 μ)), adenosine 5′‐O‐(3‐thiotriphosphate) (ATPγS), guanosine 5′‐triphosphate (GTP), inosine 5′‐triphosphate (ITP) depolarized ganglia in a concentration‐dependent manner. The relative order of ZTP and purine 5′‐triphosphates in depolarizing ganglia was ZTP≥ATPγS &gt; &gt; ATP ≥ ITP=GTP, and for the pyrimidine 5′‐triphosphates UTP &gt; TTP ≥ CTP. Depolarizations evoked by ATPγS were followed by concentration‐dependent hyperpolarizations at 100 and 1000 μm. 3 At concentrations of between 0.1 μm and 1 mm, uridine 5′‐diphosphate (UDP), uridine 5′‐diphospho‐glucose (UDPG) and uridine 5′‐diphosphoglucuronic acid (UDPGA) evoked significant and concentration‐dependent depolarizations, whereas uridine 5′‐monophosphate (UMP), uridine and uracil were inactive or produced small (&lt; 45 μV) depolarizations. The relative order of potency of uridine analogues in depolarizing ganglia was UDP ≥ UTP &gt; UDPG &gt; UDPGA &gt; &gt; uracil≥ UMP=pseudour‐idine≥ uridine. At 3 and 10 mm, uridine produced concentration‐dependent hyperpolarizations. Nikkomycin Z, a nucleoside resembling UTP (viz. the triphosphate chain at the 5′‐position on the ribose moiety being replaced by a peptide), was inactive between 1 μm and 1 mm. Generally, a concentration of 10 mm was required before thymidine, 6‐azathymine, 6‐azauracil or 6‐azauridine depolarized ganglia. 4 Suramin (300 μm), a P2‐purinoceptor antagonist, significantly depressed depolarizations evoked by α,β‐methylene‐ATP (α,β‐MeATP; 100 μm), ATPγS (100 μm), CTP (1 μm), GTP (1 μm), ZTP (30 μm) and ATP (300 μm) in the presence of DPCPX (1 μm). Suramin reversed a small depolarization evoked by UMP (1 μm) into a small hyperpolarization. In contrast depolarizations evoked by UDP, UTP, UDPG (all at 100 μm) and TTP (300 μm) were unaltered or enhanced by suramin. 5 It is concluded that the rat SCG contains distinct nucleotide receptors including a P2‐purinoceptor (activated by α,β‐MeATP, ATP, GTP, ITP and ZTP) and a pyrimidinoceptor (activated by UTP, UDP, UDPG, UDPGA and TTP). The pyrimidinoceptor on rat SCG neurones had specific structure activity requirements with the di‐ and triphosphates of uridine being the most effective depolarizing agonists examined.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8591002</pmid><doi>10.1111/j.1476-5381.1995.tb17239.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 1995-11, Vol.116 (6), p.2764-2770
issn 0007-1188
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1909137
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Adenosine 5′‐triphosphate
Aminoglycosides
Aminoimidazole Carboxamide - pharmacology
Animals
Anti-Bacterial Agents - pharmacology
Biological and medical sciences
Fundamental and applied biological sciences. Psychology
Male
Membrane Potentials - drug effects
nucleotide
P2‐purinoceptor
Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ
Pyrimidine Nucleosides - metabolism
Pyrimidine Nucleosides - pharmacology
Pyrimidine Nucleotides - metabolism
Pyrimidine Nucleotides - pharmacology
Pyrimidines - metabolism
Pyrimidines - pharmacology
pyrimidinoceptor
Rats
Rats, Sprague-Dawley
Receptors, Cell Surface - drug effects
Receptors, Cell Surface - physiology
Ribonucleotides - pharmacology
Structure-Activity Relationship
superior cervical ganglion (SCG)
Superior Cervical Ganglion - drug effects
Superior Cervical Ganglion - ultrastructure
Suramin - pharmacology
Uridine - analogs & derivatives
Uridine - pharmacology
uridine 5′‐triphosphate
Uridine Triphosphate - pharmacology
Vertebrates: nervous system and sense organs
title Structure‐activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T22%3A15%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structure%E2%80%90activity%20relationship%20of%20a%20pyrimidine%20receptor%20in%20the%20rat%20isolated%20superior%20cervical%20ganglion&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Connolly,%20G.P.&rft.date=1995-11&rft.volume=116&rft.issue=6&rft.spage=2764&rft.epage=2770&rft.pages=2764-2770&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1111/j.1476-5381.1995.tb17239.x&rft_dat=%3Cproquest_pubme%3E77827649%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17047795&rft_id=info:pmid/8591002&rfr_iscdi=true